Product Information
ALCLOMETASONE DIPRO 0.05% CRM is a generic product labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., priced at $1.2482 per GM under NDC 00168026360. Its NADAC has been published 652 times since Nov 28, 2013.
FDA first approved this application on Jul 12, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/g
NDC
00168026360
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
5/20/2026
Active Ingredients
ALCLOMETASONE DIPROPIONATEApproval Type
Generic (ANDA)
FDA Application
ANDA076973FDA Approved
7/12/2005
TE Code
AB
On Market Since
7/12/2005
Pharmacological Classes
Price Statistics
The NADAC for ALCLOMETASONE DIPRO 0.05% CRM has been published 652 times since Nov 28, 2013, and over the history we have for it it has risen 4.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2482 per GM |
|---|---|
| All-time high | $1.3764 (May 14, 2014) |
| All-time low | $0.4284 (Jul 17, 2024) |
| 52-week high | $1.2482 |
| 52-week low | $0.5721 |
| Median price | $0.9688 |
| Average price | $0.9348 |
| Largest weekly change | +110.5% (Feb 18, 2026) |
| Weeks tracked | 652 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
+2.2%
1Y
+118.2%
3Y
+84.3%
5Y
+38.5%
All
+4.8%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 56% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
alclometasone dipropionate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALCLOMETASONE DIPRO 0.05% CRM?
The current National Average Drug Acquisition Cost (NADAC) for ALCLOMETASONE DIPRO 0.05% CRM, manufactured by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., is $1.2482 per GM (NDC 00168026360), effective May 20, 2026.
How has the price of ALCLOMETASONE DIPRO 0.05% CRM changed over time?
Over the history we have for it, the NADAC for ALCLOMETASONE DIPRO 0.05% CRM has risen 4.8%. It has been tracked across 652 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ALCLOMETASONE DIPRO 0.05% CRM?
Since Nov 28, 2013, the NADAC for ALCLOMETASONE DIPRO 0.05% CRM has ranged from a low of $0.4284 (Jul 17, 2024) to a high of $1.3764 (May 14, 2014), with a median of $0.9688 per GM.
Are there cheaper alternatives to ALCLOMETASONE DIPRO 0.05% CRM?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ALCLOMETASONE DIPRO 0.05% CRM, is $0.5518 per GM — about 56% below ALCLOMETASONE DIPRO 0.05% CRM.
Who manufactures ALCLOMETASONE DIPRO 0.05% CRM?
ALCLOMETASONE DIPRO 0.05% CRM (NDC 00168026360) is labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., and CMS classifies it as a generic product.